A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Sun Yat-sen University2,000 enrolled

Overview

The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Diffuse Large B Cell Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed diagnosis of CD20+ DLBCL Exclusion Criteria: * primary central nervous system lymphoma * "double-hit" lymphoma

Locations (3)

Guangdong General Hospital

Guangzhou, Guangdong, China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,

Guangzhou, China

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,

Guangzhou, China

Outcomes

Primary Outcomes

Overall survival

Time frame: 5-year

Central Contacts

Qingqing Cai, MD

CONTACT

0086-20-87342823 caiqq@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.